Article(id=1329870830844097055, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329870817564930400, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2023.06.017, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1670515200000, receivedDateStr=2022-12-09, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794995513877, onlineDateStr=2026-11-18, pubDate=1686326400000, pubDateStr=2023-06-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794995513877, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794995513877, creator=13701087609, updateTime=1794995513877, updator=13701087609, issue=Issue{id=1329870817564930400, tenantId=1146029695717560320, journalId=1319690329412173987, year='2023', volume='44', issue='6', pageStart='525', pageEnd='667', issueExtLink='null', onlineDate='null', pubDate='1686326400000', pubDateStr='2023-06-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794995510712, creator='13701087609', updateTime=1794995908100, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329872484775604701, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329870817564930400, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329872484775604702, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329870817564930400, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=614, endPage=620, ext={EN=ArticleExt(id=1329870831041229344, articleId=1329870830844097055, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Efficacy and safety of apatinib monotherapy or in combination wtih duvarizumab in the treatment of advanced colorectal cancer, columnId=1325221089055486019, journalTitle=World Clinical Drug, columnName=Article, runingTitle=null, highlight=null, articleAbstract=
Objective

To evaluate the efficacy and safety of third-line treatment of duvarizumab combined with apatinib in the treatment of unresectable advanced colorectal cancer (CRC).

Methods

Sixty-six unresectable advanced CRC patients who received combination therapy (combination group, n=30) or apatinib monotherapy (monotherapy group, n=36) as third-line treatment were included. All patients were treated until intolerance or disease progression. The overall treatment response, objective response rate, disease control rate and incidence of adverse events were compared between the two groups.

Results

The overall response in the combination group was higher than that of the monotherapy group (P=0.025). The rates of complete response, partial response, stable disease, and disease progression in the combination group were 0, 26.67%, 50.00%, and 23.33%, respectively. Meanwhile, those in the monotherapy group were 0, 8.33%, 47.23%, and 44.44%, respectively. The objective response rate in the combination group was higher than that in the monotherapy group (26.67% vs 8.33%, P=0.047), but the difference was not statistically significant in disease control rate between the two groups (76.67% vs 55.56%, P=0.073). The progression-free survival (median: 8.60 months vs 4.50 months, P=0.012) and overall survival (median: 15.70 months vs 8.10 months, P=0.009) of combination group were superior to those of the monotherapy group. The incidence of adverse events in the combination group was similar to that in the monotherapy group (P>0.05). Most adverse events in the combination group were grade 1 - 2, and only 7 patients (23.33%) had grade 3 - 4 adverse events.

Conclusion

Third-line treatment of duvaliuzumab combined with apatinib could improve the response rate and prolong survival in patients with unresectable advanced CRC with an acceptable safety profile.

, authors=Ruiling DING, Yunchang YAO, Yao WANG*, authorsList=Ruiling DING, Yunchang YAO, Yao WANG, authorCompany=null, correspAuthors=Yao WANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329870831263527457, articleId=1329870830844097055, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=阿帕替尼单用或联合度伐利尤单抗治疗晚期结直肠癌的有效性和安全性研究, columnId=1325221089235841093, journalTitle=世界临床药物, columnName=研究论文, runingTitle=null, highlight=null, articleAbstract=
目的

评估度伐利尤单抗联合阿帕替尼(联合用药)三线治疗不可切除的晚期结直肠癌(colorectal cancer,CRC)的有效性和安全性。

方法

纳入66例接受联合用药(联合组,n=30)或阿帕替尼单药(单药组,n=36)作为三线治疗不可切除的晚期CRC患者。两组患者均给药治疗至不可耐受或疾病进展,对比两组总体治疗应答、客观反应率、疾病控制率、不良事件发生率等。

结果

联合组的总体治疗应答高于单药组(P=0.025),其中联合组的完全缓解、部分缓解、疾病稳定及疾病进展率分别为0、26.67%、50.00%和23.33%,单药组分别为0、8.33%、47.23%和44.44%。联合组的客观反应率高于单药组(26.67% vs 8.33%,P=0.047),但两组的疾病控制率差异无统计学意义(76.67% vs 55.56%,P=0.073)。联合组的无进展生存期(中位值:8.60个月vs 4.50个月,P=0.012)和总生存期(中位值:15.70个月vs 8.10个月,P=0.009)均优于对照组。联合组的不良事件发生率与单药组相似(P>0.05)。联合组大部分不良事件均为1~2级,仅7例患者(23.33%)发生3~4级不良事件。

结论

度伐利尤单抗联合阿帕替尼三线治疗不可切除的晚期CRC可提高应答率,延长生存且安全性良好。

, authors=丁瑞玲, 姚云昌, 王尧*, authorsList=丁瑞玲, 姚云昌, 王尧, authorCompany=null, correspAuthors=王尧, authorNote=

丁瑞玲,主管药师,研究方向:临床合理性用药及药物经济学。

, correspAuthorsNote=
王尧,主管药师,研究方向:临床药物管理和药剂科质控管理等。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=mUZLQNiKiMJPlDK3KTkZ0g==, magXml=WuoobGzvRMO9Ozq9/T4Qtw==, pdfUrl=null, pdf=f1FBWZuLU5raO5r80VdpWg==, pdfFileSize=1715472, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=R6tiY1F4UAAdYeN3SsXTUg==, mapNumber=null, fund=null)}, authors=[Author(id=1329870831569711654, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329870831641014824, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, authorId=1329870831569711654, language=EN, stringName=Ruiling DING, firstName=Ruiling, middleName=null, lastName=DING, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870831703929385, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, authorId=1329870831569711654, language=CN, stringName=丁瑞玲, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=鄂尔多斯市中心医院药剂科,内蒙古 鄂尔多斯 017010, bio={"content":"

丁瑞玲,主管药师,研究方向:临床合理性用药及药物经济学。

"}, bioImg=null, bioContent=

丁瑞玲,主管药师,研究方向:临床合理性用药及药物经济学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870831502602786, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, xref=null, ext=[AuthorCompanyExt(id=1329870831510991395, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, companyId=1329870831502602786, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China), AuthorCompanyExt(id=1329870831519380004, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, companyId=1329870831502602786, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=鄂尔多斯市中心医院药剂科,内蒙古 鄂尔多斯 017010)])]), Author(id=1329870831771038251, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329870831838147117, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, authorId=1329870831771038251, language=EN, stringName=Yunchang YAO, firstName=Yunchang, middleName=null, lastName=YAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870831913644590, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, authorId=1329870831771038251, language=CN, stringName=姚云昌, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=鄂尔多斯市中心医院药剂科,内蒙古 鄂尔多斯 017010, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870831502602786, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, xref=null, ext=[AuthorCompanyExt(id=1329870831510991395, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, companyId=1329870831502602786, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China), AuthorCompanyExt(id=1329870831519380004, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, companyId=1329870831502602786, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=鄂尔多斯市中心医院药剂科,内蒙古 鄂尔多斯 017010)])]), Author(id=1329870831997530672, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329870832064639538, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, authorId=1329870831997530672, language=EN, stringName=Yao WANG, firstName=Yao, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870832123359795, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, authorId=1329870831997530672, language=CN, stringName=王尧, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=鄂尔多斯市中心医院药剂科,内蒙古 鄂尔多斯 017010, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870831502602786, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, xref=null, ext=[AuthorCompanyExt(id=1329870831510991395, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, companyId=1329870831502602786, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China), AuthorCompanyExt(id=1329870831519380004, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, companyId=1329870831502602786, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=鄂尔多斯市中心医院药剂科,内蒙古 鄂尔多斯 017010)])])], keywords=[Keyword(id=1329870832224023092, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, language=EN, orderNo=1, keyword=apatinib), Keyword(id=1329870832354046517, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, language=EN, orderNo=2, keyword=duvarizumab), Keyword(id=1329870832412766774, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, language=EN, orderNo=3, keyword=advanced colorectal cancer), Keyword(id=1329870832471487031, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, language=EN, orderNo=4, keyword=efficacy), Keyword(id=1329870832526012984, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, language=EN, orderNo=5, keyword=safety), Keyword(id=1329870832593121849, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, language=CN, orderNo=1, keyword=阿帕替尼), Keyword(id=1329870832651842106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, language=CN, orderNo=2, keyword=度伐利尤单抗), Keyword(id=1329870832765088315, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, language=CN, orderNo=3, keyword=晚期结直肠癌), Keyword(id=1329870832832197180, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, language=CN, orderNo=4, keyword=有效性), Keyword(id=1329870832991580733, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, language=CN, orderNo=5, keyword=安全性)], refs=[Reference(id=1329870833079661118, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Baidoun F, Elshiwy K, Elkeraie Y, et al. Colorectal cancer epidemiology: recent trends and impact on outcomes[J]. Curr Drug Targets, 2021, 22(9): 998-1009., articleTitle=null, refAbstract=null), Reference(id=1329870833142575679, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040[J]. Transl Oncol, 2021, 14(10): 101174., articleTitle=null, refAbstract=null), Reference(id=1329870833213878848, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Aparicio J, Esposito F, Serrano S, et al. Metastatic colorectal cancer. first line therapy for unresectable disease[J]. J Clin Med, 2020, 9(12): 3889., articleTitle=null, refAbstract=null), Reference(id=1329870833285182017, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Davies J, Chew C, Bromham N, et al. NICE 2020 guideline for the management of colorectal cancer[J]. Lancet Oncol, 2022, 23(6): e247., articleTitle=null, refAbstract=null), Reference(id=1329870833373262402, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Force USPST, Davidson KW, Barry MJ, et al. Screening for colorectal cancer: US preventive services task force recommendation statement[J]. J Am Med Assoc, 2021, 325(19): 1965-1977., articleTitle=null, refAbstract=null), Reference(id=1329870833436176963, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhao L, Yu Q, Gao C, et al. Studies of the efficacy of low-dose apatinib monotherapy as third-line treatment in patients with metastatic colorectal cancer and apatinib's novel anticancer effect by inhibiting tumor-derived exosome secretion[J]. Cancers (Basel), 2022, 14(10): 2492., articleTitle=null, refAbstract=null), Reference(id=1329870833499091524, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Dai Y, Sun L, Zhuang L, et al. Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study[J]. J Gastrointest Oncol, 2022, 13(2): 722-731., articleTitle=null, refAbstract=null), Reference(id=1329870833553617477, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Segal NH, Cercek A, Ku G, et al. Phase Ⅱ single-arm study of durvalumab and tremelimumab with concurrent radiotherapy in patients with mismatch repair-proficient metastatic colorectal cancer[J]. Clin Cancer Res, 2021, 27(8): 2200-2208., articleTitle=null, refAbstract=null), Reference(id=1329870833620726342, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang Q, Gao J, Di W, et al. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models[J]. Cancer Immunol Immunother, 2020, 69(9): 1781-1799., articleTitle=null, refAbstract=null), Reference(id=1329870833679446599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen EX, Jonker DJ, Loree JM, et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer the Canadian cancer trials group CO. 26 study[J]. J Am Med Assoc Oncol, 2020, 6(6): 831-838., articleTitle=null, refAbstract=null), Reference(id=1329870833742361160, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Ren C, Mai ZJ, Jin Y, et al. Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase Ⅱ trial[J]. Am J Cancer Res, 2020, 10(9): 2946-2954., articleTitle=null, refAbstract=null), Reference(id=1329870833801081417, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Pan D, Liu D, Liang L, et al. Treatment response, survival benefit and safety profile of PD-1 inhibitor plus apatinib versus apatinib monotherapy in advanced colorectal cancer patients[J]. Front Oncol, 2022, 12: 863392., articleTitle=null, refAbstract=null), Reference(id=1329870833855607370, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Neumann M, Murphy N, Seetharamu N. The evolving role of PD-L1 inhibition in non-small cell lung cancer: a review of durvalumab and avelumab[J]. Cancer Med J, 2022, 5(1): 31-45., articleTitle=null, refAbstract=null), Reference(id=1329870833926910539, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu J, Chen Z, Li Y, et al. PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy[J]. Front Pharmacol, 2021, 12: 731798., articleTitle=null, refAbstract=null), Reference(id=1329870833977242188, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Sun J, Zheng Y, Mamun M, et al. Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors[J]. Biomed Pharmacother, 2020, 129: 110504., articleTitle=null, refAbstract=null), Reference(id=1329870834040156749, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Ge J, Huang X, Wang P, et al. Expression of biogenesis of ribosomes BRX1 is associated with malignant progression and prognosis in colorectal cancer[J]. Transl Cancer Res, 2020, 9(9): 5595-5602., articleTitle=null, refAbstract=null), Reference(id=1329870834111459918, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Lau SCM, Ryan M, Weiss J, et al. Concurrent chemoradiation with or without durvalumab in elderly patients with unresectable stage Ⅲ NSCLC: safety and efficacy[J]. JTO Clin Res Rep, 2021, 2(12): 100251., articleTitle=null, refAbstract=null), Reference(id=1329870834186957391, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Liao X, Li H, Liu Z, et al. Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment[J]. Medicine (Baltimore), 2018, 97(50): e13635., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329870831502602786, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, xref=null, ext=[AuthorCompanyExt(id=1329870831510991395, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, companyId=1329870831502602786, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China), AuthorCompanyExt(id=1329870831519380004, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, companyId=1329870831502602786, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=鄂尔多斯市中心医院药剂科,内蒙古 鄂尔多斯 017010)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.06.017, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.06.017, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2023.06.017, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2023.06.017, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1686326400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
阿帕替尼单用或联合度伐利尤单抗治疗晚期结直肠癌的有效性和安全性研究
丁瑞玲 , 姚云昌 , 王尧 *
世界临床药物 | 研究论文 2023,44(6): 614-620
收起
收藏切换
世界临床药物 |研究论文 2023 , 44 (6) : 614 -620
阿帕替尼单用或联合度伐利尤单抗治疗晚期结直肠癌的有效性和安全性研究
全屏
[Author(id=1329870831569711654, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329870831641014824, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, authorId=1329870831569711654, language=EN, stringName=Ruiling DING, firstName=Ruiling, middleName=null, lastName=DING, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870831703929385, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, authorId=1329870831569711654, language=CN, stringName=丁瑞玲, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=鄂尔多斯市中心医院药剂科,内蒙古 鄂尔多斯 017010, bio={"content":"

丁瑞玲,主管药师,研究方向:临床合理性用药及药物经济学。

"}, bioImg=null, bioContent=

丁瑞玲,主管药师,研究方向:临床合理性用药及药物经济学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870831502602786, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, xref=null, ext=[AuthorCompanyExt(id=1329870831510991395, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, companyId=1329870831502602786, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China), AuthorCompanyExt(id=1329870831519380004, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, companyId=1329870831502602786, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=鄂尔多斯市中心医院药剂科,内蒙古 鄂尔多斯 017010)])]), Author(id=1329870831771038251, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329870831838147117, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, authorId=1329870831771038251, language=EN, stringName=Yunchang YAO, firstName=Yunchang, middleName=null, lastName=YAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870831913644590, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, authorId=1329870831771038251, language=CN, stringName=姚云昌, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=鄂尔多斯市中心医院药剂科,内蒙古 鄂尔多斯 017010, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870831502602786, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, xref=null, ext=[AuthorCompanyExt(id=1329870831510991395, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, companyId=1329870831502602786, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China), AuthorCompanyExt(id=1329870831519380004, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, companyId=1329870831502602786, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=鄂尔多斯市中心医院药剂科,内蒙古 鄂尔多斯 017010)])]), Author(id=1329870831997530672, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329870832064639538, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, authorId=1329870831997530672, language=EN, stringName=Yao WANG, firstName=Yao, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870832123359795, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, authorId=1329870831997530672, language=CN, stringName=王尧, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=鄂尔多斯市中心医院药剂科,内蒙古 鄂尔多斯 017010, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870831502602786, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, xref=null, ext=[AuthorCompanyExt(id=1329870831510991395, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, companyId=1329870831502602786, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China), AuthorCompanyExt(id=1329870831519380004, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870830844097055, companyId=1329870831502602786, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=鄂尔多斯市中心医院药剂科,内蒙古 鄂尔多斯 017010)])])]
丁瑞玲, 姚云昌, 王尧*
作者信息
  • 鄂尔多斯市中心医院药剂科,内蒙古 鄂尔多斯 017010
通讯作者:
王尧,主管药师,研究方向:临床药物管理和药剂科质控管理等。
作者简介:

丁瑞玲,主管药师,研究方向:临床合理性用药及药物经济学。

Efficacy and safety of apatinib monotherapy or in combination wtih duvarizumab in the treatment of advanced colorectal cancer
Ruiling DING, Yunchang YAO, Yao WANG*
Affiliations
  • Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China
出版时间: 2023-06-10 doi: 10.13683/j.wph.2023.06.017
文章导航
收藏切换
目的

评估度伐利尤单抗联合阿帕替尼(联合用药)三线治疗不可切除的晚期结直肠癌(colorectal cancer,CRC)的有效性和安全性。

方法

纳入66例接受联合用药(联合组,n=30)或阿帕替尼单药(单药组,n=36)作为三线治疗不可切除的晚期CRC患者。两组患者均给药治疗至不可耐受或疾病进展,对比两组总体治疗应答、客观反应率、疾病控制率、不良事件发生率等。

结果

联合组的总体治疗应答高于单药组(P=0.025),其中联合组的完全缓解、部分缓解、疾病稳定及疾病进展率分别为0、26.67%、50.00%和23.33%,单药组分别为0、8.33%、47.23%和44.44%。联合组的客观反应率高于单药组(26.67% vs 8.33%,P=0.047),但两组的疾病控制率差异无统计学意义(76.67% vs 55.56%,P=0.073)。联合组的无进展生存期(中位值:8.60个月vs 4.50个月,P=0.012)和总生存期(中位值:15.70个月vs 8.10个月,P=0.009)均优于对照组。联合组的不良事件发生率与单药组相似(P>0.05)。联合组大部分不良事件均为1~2级,仅7例患者(23.33%)发生3~4级不良事件。

结论

度伐利尤单抗联合阿帕替尼三线治疗不可切除的晚期CRC可提高应答率,延长生存且安全性良好。

阿帕替尼  /  度伐利尤单抗  /  晚期结直肠癌  /  有效性  /  安全性
Objective

To evaluate the efficacy and safety of third-line treatment of duvarizumab combined with apatinib in the treatment of unresectable advanced colorectal cancer (CRC).

Methods

Sixty-six unresectable advanced CRC patients who received combination therapy (combination group, n=30) or apatinib monotherapy (monotherapy group, n=36) as third-line treatment were included. All patients were treated until intolerance or disease progression. The overall treatment response, objective response rate, disease control rate and incidence of adverse events were compared between the two groups.

Results

The overall response in the combination group was higher than that of the monotherapy group (P=0.025). The rates of complete response, partial response, stable disease, and disease progression in the combination group were 0, 26.67%, 50.00%, and 23.33%, respectively. Meanwhile, those in the monotherapy group were 0, 8.33%, 47.23%, and 44.44%, respectively. The objective response rate in the combination group was higher than that in the monotherapy group (26.67% vs 8.33%, P=0.047), but the difference was not statistically significant in disease control rate between the two groups (76.67% vs 55.56%, P=0.073). The progression-free survival (median: 8.60 months vs 4.50 months, P=0.012) and overall survival (median: 15.70 months vs 8.10 months, P=0.009) of combination group were superior to those of the monotherapy group. The incidence of adverse events in the combination group was similar to that in the monotherapy group (P>0.05). Most adverse events in the combination group were grade 1 - 2, and only 7 patients (23.33%) had grade 3 - 4 adverse events.

Conclusion

Third-line treatment of duvaliuzumab combined with apatinib could improve the response rate and prolong survival in patients with unresectable advanced CRC with an acceptable safety profile.

apatinib  /  duvarizumab  /  advanced colorectal cancer  /  efficacy  /  safety
丁瑞玲, 姚云昌, 王尧. 阿帕替尼单用或联合度伐利尤单抗治疗晚期结直肠癌的有效性和安全性研究. 世界临床药物, 2023 , 44 (6) : 614 -620 . DOI: 10.13683/j.wph.2023.06.017
Ruiling DING, Yunchang YAO, Yao WANG. Efficacy and safety of apatinib monotherapy or in combination wtih duvarizumab in the treatment of advanced colorectal cancer[J]. World Clinical Drug, 2023 , 44 (6) : 614 -620 . DOI: 10.13683/j.wph.2023.06.017

参考文献 引证文献
排序方式:
[1]
Baidoun F, Elshiwy K, Elkeraie Y, et al. Colorectal cancer epidemiology: recent trends and impact on outcomes[J]. Curr Drug Targets, 2021, 22(9): 998-1009.
[2]
Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040[J]. Transl Oncol, 2021, 14(10): 101174.
[3]
Aparicio J, Esposito F, Serrano S, et al. Metastatic colorectal cancer. first line therapy for unresectable disease[J]. J Clin Med, 2020, 9(12): 3889.
[4]
Davies J, Chew C, Bromham N, et al. NICE 2020 guideline for the management of colorectal cancer[J]. Lancet Oncol, 2022, 23(6): e247.
[5]
Force USPST, Davidson KW, Barry MJ, et al. Screening for colorectal cancer: US preventive services task force recommendation statement[J]. J Am Med Assoc, 2021, 325(19): 1965-1977.
[6]
Zhao L, Yu Q, Gao C, et al. Studies of the efficacy of low-dose apatinib monotherapy as third-line treatment in patients with metastatic colorectal cancer and apatinib's novel anticancer effect by inhibiting tumor-derived exosome secretion[J]. Cancers (Basel), 2022, 14(10): 2492.
[7]
Dai Y, Sun L, Zhuang L, et al. Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study[J]. J Gastrointest Oncol, 2022, 13(2): 722-731.
[8]
Segal NH, Cercek A, Ku G, et al. Phase Ⅱ single-arm study of durvalumab and tremelimumab with concurrent radiotherapy in patients with mismatch repair-proficient metastatic colorectal cancer[J]. Clin Cancer Res, 2021, 27(8): 2200-2208.
[9]
Wang Q, Gao J, Di W, et al. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models[J]. Cancer Immunol Immunother, 2020, 69(9): 1781-1799.
[10]
Chen EX, Jonker DJ, Loree JM, et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer the Canadian cancer trials group CO. 26 study[J]. J Am Med Assoc Oncol, 2020, 6(6): 831-838.
[11]
Ren C, Mai ZJ, Jin Y, et al. Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase Ⅱ trial[J]. Am J Cancer Res, 2020, 10(9): 2946-2954.
[12]
Pan D, Liu D, Liang L, et al. Treatment response, survival benefit and safety profile of PD-1 inhibitor plus apatinib versus apatinib monotherapy in advanced colorectal cancer patients[J]. Front Oncol, 2022, 12: 863392.
[13]
Neumann M, Murphy N, Seetharamu N. The evolving role of PD-L1 inhibition in non-small cell lung cancer: a review of durvalumab and avelumab[J]. Cancer Med J, 2022, 5(1): 31-45.
[14]
Liu J, Chen Z, Li Y, et al. PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy[J]. Front Pharmacol, 2021, 12: 731798.
[15]
Sun J, Zheng Y, Mamun M, et al. Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors[J]. Biomed Pharmacother, 2020, 129: 110504.
[16]
Ge J, Huang X, Wang P, et al. Expression of biogenesis of ribosomes BRX1 is associated with malignant progression and prognosis in colorectal cancer[J]. Transl Cancer Res, 2020, 9(9): 5595-5602.
[17]
Lau SCM, Ryan M, Weiss J, et al. Concurrent chemoradiation with or without durvalumab in elderly patients with unresectable stage Ⅲ NSCLC: safety and efficacy[J]. JTO Clin Res Rep, 2021, 2(12): 100251.
[18]
Liao X, Li H, Liu Z, et al. Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment[J]. Medicine (Baltimore), 2018, 97(50): e13635.
2023年第44卷第6期
9
0
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2023.06.017
  • 接收时间:2022-12-09
  • 首发时间:2026-11-18
  • 出版时间:2023-06-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-12-09
基金
作者信息
    鄂尔多斯市中心医院药剂科,内蒙古 鄂尔多斯 017010

通讯作者:

王尧,主管药师,研究方向:临床药物管理和药剂科质控管理等。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.06.017
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏